Would you recommend adjuvant olaparib in a premenopausal BRCA1+ woman with stage IA pT1bN0 ER/PR+ HER2- breast cancer and a high OncoType score?

This is a data-free zone. Although this patient appears to have a high recurrence risk based on her Oncotype RS, she does not seem eligible for adjuvant olaparib based on her clinical-pathological characteristics. The Oncotype RS was not taken into consideration as part of the eligibility criteria i...

In this patient, due to the high Oncotype DX score of 51, there is likely to be a more than 15% absolute benefit of chemotherapy in terms of reducing the risk of distant recurrence based on the TAILORx study, and hence I would definitely offer her adjuvant chemotherapy.

In the OlympiA study, assessi...

Agree with the above comments and also important to note that most BRCA patients do have a high Oncotype score.